An Individual Participant Data Population Pharmacokinetic Meta-Analysis of Drug-drug Interactions between Lumefantrine and Commonly-used Antiretroviral Treatment

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

An Individual Participant Data Population Pharmacokinetic Meta-Analysis of Drug-drug Interactions between Lumefantrine and Commonly-used Antiretroviral Treatment. / Francis, Jose; Barnes, Karen I.; Workman, Lesley; Kredo, Tamara; Vestergaard, Lasse S.; Hoglund, Richard M; Byakika-Kibwika, Pauline; Lamorde, Mohammed; Walimbwa, Stephen I; Chijioke-Nwauche, Ifeyinwa; Sutherland, Colin J.; Merry, Concepta; Scarsi, Kimberley K; Nyagonde, Nyagonde; Lemnge, Martha M.; Khoo, Saye H; Bygbjerg, Ib C; Parikh, Sunil; Aweeka, Francesca T; Tarning, Joel; Denti, Paolo.

I: Antimicrobial Agents and Chemotherapy, Bind 64, Nr. 5, e02394, 2020.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Francis, J, Barnes, KI, Workman, L, Kredo, T, Vestergaard, LS, Hoglund, RM, Byakika-Kibwika, P, Lamorde, M, Walimbwa, SI, Chijioke-Nwauche, I, Sutherland, CJ, Merry, C, Scarsi, KK, Nyagonde, N, Lemnge, MM, Khoo, SH, Bygbjerg, IC, Parikh, S, Aweeka, FT, Tarning, J & Denti, P 2020, 'An Individual Participant Data Population Pharmacokinetic Meta-Analysis of Drug-drug Interactions between Lumefantrine and Commonly-used Antiretroviral Treatment', Antimicrobial Agents and Chemotherapy, bind 64, nr. 5, e02394. https://doi.org/10.1128/AAC.02394-19

APA

Francis, J., Barnes, K. I., Workman, L., Kredo, T., Vestergaard, L. S., Hoglund, R. M., Byakika-Kibwika, P., Lamorde, M., Walimbwa, S. I., Chijioke-Nwauche, I., Sutherland, C. J., Merry, C., Scarsi, K. K., Nyagonde, N., Lemnge, M. M., Khoo, S. H., Bygbjerg, I. C., Parikh, S., Aweeka, F. T., ... Denti, P. (2020). An Individual Participant Data Population Pharmacokinetic Meta-Analysis of Drug-drug Interactions between Lumefantrine and Commonly-used Antiretroviral Treatment. Antimicrobial Agents and Chemotherapy, 64(5), [e02394]. https://doi.org/10.1128/AAC.02394-19

Vancouver

Francis J, Barnes KI, Workman L, Kredo T, Vestergaard LS, Hoglund RM o.a. An Individual Participant Data Population Pharmacokinetic Meta-Analysis of Drug-drug Interactions between Lumefantrine and Commonly-used Antiretroviral Treatment. Antimicrobial Agents and Chemotherapy. 2020;64(5). e02394. https://doi.org/10.1128/AAC.02394-19

Author

Francis, Jose ; Barnes, Karen I. ; Workman, Lesley ; Kredo, Tamara ; Vestergaard, Lasse S. ; Hoglund, Richard M ; Byakika-Kibwika, Pauline ; Lamorde, Mohammed ; Walimbwa, Stephen I ; Chijioke-Nwauche, Ifeyinwa ; Sutherland, Colin J. ; Merry, Concepta ; Scarsi, Kimberley K ; Nyagonde, Nyagonde ; Lemnge, Martha M. ; Khoo, Saye H ; Bygbjerg, Ib C ; Parikh, Sunil ; Aweeka, Francesca T ; Tarning, Joel ; Denti, Paolo. / An Individual Participant Data Population Pharmacokinetic Meta-Analysis of Drug-drug Interactions between Lumefantrine and Commonly-used Antiretroviral Treatment. I: Antimicrobial Agents and Chemotherapy. 2020 ; Bind 64, Nr. 5.

Bibtex

@article{e6b8dfc4978e4bb8b25d427ae7a642c8,

title = "An Individual Participant Data Population Pharmacokinetic Meta-Analysis of Drug-drug Interactions between Lumefantrine and Commonly-used Antiretroviral Treatment",

abstract = "Treating malaria in HIV co-infected individuals should consider potential drug-drug interactions. Artemether-lumefantrine is the most widely recommended treatment for uncomplicated malaria globally. Lumefantrine is metabolized by CYP3A4, an enzyme that commonly-used antiretrovirals often induce or inhibit. A population pharmacokinetic meta-analysis was conducted using individual participant data from ten studies, with 6,100 lumefantrine concentrations from 793 non-pregnant adult participants (41% HIV-malaria co-infected, 36% malaria-infected, 20% HIV-infected, and 3% healthy volunteers). Lumefantrine exposure increased 3.4-fold with co-administration of lopinavir/ritonavir-based antiretroviral therapy (ART), while it decreased by 47% with efavirenz-based ART and by 59% in the patients with rifampicin-based anti-tuberculosis treatment. Nevirapine- or dolutegravir-based ART and malaria- or HIV-infection were not associated with significant effects. Monte Carlo simulations showed that those on concomitant efavirenz or rifampicin have 49% and 80% probability of day-7 concentrations <200 ng/mL respectively, a threshold associated with an increased risk of treatment failure. The risk of achieving sub-therapeutic concentrations increases with larger body weight. An extended 5-day and 6-day artemether-lumefantrine regimen is predicted to overcome these drug-drug interactions with efavirenz and rifampicin respectively.",

author = "Jose Francis and Barnes, {Karen I.} and Lesley Workman and Tamara Kredo and Vestergaard, {Lasse S.} and Hoglund, {Richard M} and Pauline Byakika-Kibwika and Mohammed Lamorde and Walimbwa, {Stephen I} and Ifeyinwa Chijioke-Nwauche and Sutherland, {Colin J.} and Concepta Merry and Scarsi, {Kimberley K} and Nyagonde Nyagonde and Lemnge, {Martha M.} and Khoo, {Saye H} and Bygbjerg, {Ib C} and Sunil Parikh and Aweeka, {Francesca T} and Joel Tarning and Paolo Denti",

note = "Copyright {\textcopyright} 2020 Francis et al.",

year = "2020",

doi = "10.1128/AAC.02394-19",

language = "English",

volume = "64",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "5",

}

RIS

TY - JOUR

T1 - An Individual Participant Data Population Pharmacokinetic Meta-Analysis of Drug-drug Interactions between Lumefantrine and Commonly-used Antiretroviral Treatment

AU - Francis, Jose

AU - Barnes, Karen I.

AU - Workman, Lesley

AU - Kredo, Tamara

AU - Vestergaard, Lasse S.

AU - Hoglund, Richard M

AU - Byakika-Kibwika, Pauline

AU - Lamorde, Mohammed

AU - Walimbwa, Stephen I

AU - Chijioke-Nwauche, Ifeyinwa

AU - Sutherland, Colin J.

AU - Merry, Concepta

AU - Scarsi, Kimberley K

AU - Nyagonde, Nyagonde

AU - Lemnge, Martha M.

AU - Khoo, Saye H

AU - Bygbjerg, Ib C

AU - Parikh, Sunil

AU - Aweeka, Francesca T

AU - Tarning, Joel

AU - Denti, Paolo

PY - 2020

Y1 - 2020

N2 - Treating malaria in HIV co-infected individuals should consider potential drug-drug interactions. Artemether-lumefantrine is the most widely recommended treatment for uncomplicated malaria globally. Lumefantrine is metabolized by CYP3A4, an enzyme that commonly-used antiretrovirals often induce or inhibit. A population pharmacokinetic meta-analysis was conducted using individual participant data from ten studies, with 6,100 lumefantrine concentrations from 793 non-pregnant adult participants (41% HIV-malaria co-infected, 36% malaria-infected, 20% HIV-infected, and 3% healthy volunteers). Lumefantrine exposure increased 3.4-fold with co-administration of lopinavir/ritonavir-based antiretroviral therapy (ART), while it decreased by 47% with efavirenz-based ART and by 59% in the patients with rifampicin-based anti-tuberculosis treatment. Nevirapine- or dolutegravir-based ART and malaria- or HIV-infection were not associated with significant effects. Monte Carlo simulations showed that those on concomitant efavirenz or rifampicin have 49% and 80% probability of day-7 concentrations <200 ng/mL respectively, a threshold associated with an increased risk of treatment failure. The risk of achieving sub-therapeutic concentrations increases with larger body weight. An extended 5-day and 6-day artemether-lumefantrine regimen is predicted to overcome these drug-drug interactions with efavirenz and rifampicin respectively.

AB - Treating malaria in HIV co-infected individuals should consider potential drug-drug interactions. Artemether-lumefantrine is the most widely recommended treatment for uncomplicated malaria globally. Lumefantrine is metabolized by CYP3A4, an enzyme that commonly-used antiretrovirals often induce or inhibit. A population pharmacokinetic meta-analysis was conducted using individual participant data from ten studies, with 6,100 lumefantrine concentrations from 793 non-pregnant adult participants (41% HIV-malaria co-infected, 36% malaria-infected, 20% HIV-infected, and 3% healthy volunteers). Lumefantrine exposure increased 3.4-fold with co-administration of lopinavir/ritonavir-based antiretroviral therapy (ART), while it decreased by 47% with efavirenz-based ART and by 59% in the patients with rifampicin-based anti-tuberculosis treatment. Nevirapine- or dolutegravir-based ART and malaria- or HIV-infection were not associated with significant effects. Monte Carlo simulations showed that those on concomitant efavirenz or rifampicin have 49% and 80% probability of day-7 concentrations <200 ng/mL respectively, a threshold associated with an increased risk of treatment failure. The risk of achieving sub-therapeutic concentrations increases with larger body weight. An extended 5-day and 6-day artemether-lumefantrine regimen is predicted to overcome these drug-drug interactions with efavirenz and rifampicin respectively.

U2 - 10.1128/AAC.02394-19

DO - 10.1128/AAC.02394-19

M3 - Journal article

C2 - 32071050

VL - 64

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 5

M1 - e02394

ER -

ID: 236602707